Jaap Bremer

T: +31 70 376 06 25
E: jaap.bremer@barentskrans.nl
View Jaap Bremer on LinkedIn

Jaap’s practice focuses on Intellectual Property litigation, in particular with respect to patents, trademarks and advertising. Jaap has extensive experience in infringement and invalidity litigation, as well as in parallel import, anti-counterfeiting and customs enforcement matters, particularly for clients in the pharma & life sciences, food & beverage and consumer products industries. He also regularly advises clients in non-contentious matters, including negotiation and drafting of licence and coexistence agreements. Jaap is internationally recognized as a specialist in both patent law and trademark and copyright law. In Chambers 2020, he was the only lawyer in the Netherlands to be ranked in both categories.

Selected directory listings

‘Jaap Bremer is a top quality advocate and legal practitioner, adept at rapidly getting to grips with complex technologies.‘ – Legal 500, 2021

Jaap Bremer is a standout trade mark lawyer, combining legal knowledge with a practical, commercial application and also Jaap Bremer: hands-on, practical advice combined with an open mind to handle matters, leading to solutions that the business can always work with. ‘Experienced litigator and negotiator.’ – Legal 500, 2021

Jaap Bremer is active on both trade mark and patent disputes. His adroit manner of communication is underlined by clients, one informing of his “ability to quickly grasp the essence of a case, which he can then explain in easy-to-understand language accurately to the client and the judges.” – Chambers Europe 2021

Jaap Bremer is recommended as an ‘excellent advocate‘ who is ‘highly competent, pragmatic and deliberate‘. – Legal 500, 2020

Clients regard Jaap Bremer as a “down-to-earth straight-shooter” who is “very solid and personable.” He acts on cases relating to both trade mark and patent disputes. – Chambers  Global & Europe 2020

Clients regard Jaap Bremer as a “down-to-earth straight-shooter” who is “very solid and personable.” He acts on cases relating to both trade mark and patent disputes. – Chambers Global & Europe 2020

Professional activities

  • Member of Editorial Board EPLAW Patent Blog
  • Active member of the International Trademark Association (INTA)
  • Member of various professional associations, including EPLAW, PTMG, LES, BMM, VFenR, VvRr and MARQUES
  • Member of Vereniging Intellectuele Eigendom Proces Advocaten (VIEPA)

Recently from this specialist

Telecoms update | District Court rejects infringement claim

On 30 December 2020 (published 13 January 2021), the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings initiated by Adaptive Spectrum and Signal Alignment, Incorporated (“ASSIA”) against Koninklijke KPN N.V., Telfort Zakelijk B.V., XS4ALL Internet B.V., KPN B.V. (collectively “KPN”) and Nokia Solutions and Networks Nederland B.V. (“Nokia”) regarding
Read more ›

Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent

In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›

Pharma update | Cross-border preliminary injunction granted regarding deferasirox

At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient
Read more ›

Pharma update | NPS’s cinacalcet patent held valid by Court of Appeal

EP ‘761, owned by Shire-NPS Pharmaceuticals Inc. (‘NPS’), relates to the API cinacalcet, which is used for the treatment of conditions of impaired regulation of calcium levels in human blood and tissue fluid. The product is marketed under the name Mimpara®. In September 2017, Accord Healthcare Ltd. and Accord Healthcare B.V. (‘Accord’) initiated invalidity proceedings
Read more ›
More from this specialist